{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T23:26:12Z","timestamp":1783207572766,"version":"3.54.6"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.bbmt.2020.08.012","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T22:21:39Z","timestamp":1597702899000},"page":"2217-2222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience"],"prefix":"10.1016","volume":"26","author":[{"given":"Arushi","family":"Khurana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana N.","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy R.","family":"LaPlant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Patrick O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Inwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Porrata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C. Villasboas","family":"Bisneto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.08.012_bib0001","doi-asserted-by":"crossref","unstructured":"Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985-19991. Neuro Oncol. 2006;8(1):27-37.","DOI":"10.1215\/S1522851705000323"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0002","doi-asserted-by":"crossref","unstructured":"Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105(9):1414-1418.","DOI":"10.1038\/bjc.2011.357"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0003","doi-asserted-by":"crossref","unstructured":"Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019;21(5):v1-v100.","DOI":"10.1093\/neuonc\/noz150"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0004","doi-asserted-by":"crossref","unstructured":"O'Neill BP, Decker PA, Tieu C, Cerhan JR. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma. Am J Hematol. 2013;88(12):997-1000.","DOI":"10.1002\/ajh.23551"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0005","doi-asserted-by":"crossref","unstructured":"Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system nonHodgkin's lymphoma. The Massachusetts General Hospital experience 1958\u20101989. Cancer. 1994;74(4):1383-1397.","DOI":"10.1002\/1097-0142(19940815)74:4<1383::AID-CNCR2820740432>3.0.CO;2-1"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0006","doi-asserted-by":"crossref","unstructured":"Abrey LE, Batchelor TT, Ferreri AJM, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-5043.","DOI":"10.1200\/JCO.2005.13.524"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0007","doi-asserted-by":"crossref","unstructured":"Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061-3068.","DOI":"10.1200\/JCO.2012.46.9957"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0008","doi-asserted-by":"crossref","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217-e227.","DOI":"10.1016\/S2352-3026(16)00036-3"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0009","doi-asserted-by":"crossref","unstructured":"Omuro A, Chinot O, Taillandier L, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015;2(6):e251-e259.","DOI":"10.1016\/S2352-3026(15)00074-5"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0010","doi-asserted-by":"crossref","unstructured":"Herrlinger U, K\u00fcker W, Uhl M, et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol. 2005;57(6):843-847.","DOI":"10.1002\/ana.20495"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0011","doi-asserted-by":"crossref","unstructured":"Pels H, Schmidt-Wolf IGH, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21(24):4489-4495.","DOI":"10.1200\/JCO.2003.04.056"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0012","doi-asserted-by":"crossref","unstructured":"Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21(6):1044-1049.","DOI":"10.1200\/JCO.2003.03.036"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0013","doi-asserted-by":"crossref","unstructured":"Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24(28):4570-4574.","DOI":"10.1200\/JCO.2006.06.6910"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0014","doi-asserted-by":"crossref","unstructured":"Omuro AMP, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005;62(10):1595-1600.","DOI":"10.1001\/archneur.62.10.1595"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0015","doi-asserted-by":"crossref","unstructured":"Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036-1047.","DOI":"10.1016\/S1470-2045(10)70229-1"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0016","doi-asserted-by":"crossref","unstructured":"Korfel A, Thiel E, Martus P, et al. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology. 2015;84(12):1242-1248.","DOI":"10.1212\/WNL.0000000000001395"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0017","doi-asserted-by":"crossref","unstructured":"Illerhaus G, Kasenda B, Ihorst G, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol. 2016;3(8):e388-e397.","DOI":"10.1016\/S2352-3026(16)30050-3"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0018","doi-asserted-by":"crossref","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510-e523.","DOI":"10.1016\/S2352-3026(17)30174-6"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0019","doi-asserted-by":"crossref","unstructured":"Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma-a long-term follow-up study. Ann Oncol. 2012;23(10):2670-2675.","DOI":"10.1093\/annonc\/mds059"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0020","doi-asserted-by":"crossref","unstructured":"Alnahhas I, Jawish M, Alsawas M, et al. Autologous stem-cell transplantation for primary central nervous system lymphoma: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2019;19(3):e129-e141.","DOI":"10.1016\/j.clml.2018.11.018"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0021","doi-asserted-by":"crossref","unstructured":"Ferreri AJM, Illerhaus G.The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood. 2016;127(13):1642-1649.","DOI":"10.1182\/blood-2015-10-636340"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0022","doi-asserted-by":"crossref","unstructured":"Jos\u00e9 A, Ferreri M, Centre J-YB, B\u00e9rard L, Spina M.Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group Experience. J Clin Oncol. 2003;21(2):266-272.","DOI":"10.1200\/JCO.2003.09.139"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0023","doi-asserted-by":"crossref","unstructured":"Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003;21(22):4151-4156.","DOI":"10.1200\/JCO.2003.05.024"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0024","doi-asserted-by":"crossref","unstructured":"Glass J, Won M, Schultz CJ, et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227. J Clin Oncol. 2016;34(14):1620-1625.","DOI":"10.1200\/JCO.2015.64.8634"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0025","doi-asserted-by":"crossref","unstructured":"Colombat P, Lemevel A, Bertrand P, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006;38(6):417-420.","DOI":"10.1038\/sj.bmt.1705452"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0026","doi-asserted-by":"crossref","unstructured":"Wiebe VJ, Smith BR, DeGregorio MW, Rappeport JM.Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol. 1992;13(3):241-270.","DOI":"10.1016\/1040-8428(92)90092-5"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0027","doi-asserted-by":"crossref","unstructured":"Illerhaus G, M\u00fcller F, Feuerhake F, Sch\u00e4fer AO, Ostertag C, Finke J.High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93(1):147-148.","DOI":"10.3324\/haematol.11771"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0028","doi-asserted-by":"crossref","unstructured":"Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24(24):3865-3870.","DOI":"10.1200\/JCO.2006.06.2117"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0029","doi-asserted-by":"crossref","unstructured":"Kondo E, Ikeda T, Izutsu K, et al. High-dose chemotherapy with autologous stem cell transplantation in primary central nervous system lymphoma: data from the Japan Society for Hematopoietic Cell Transplantation Registry. Biol Blood Marrow Transplant. 2019;25(5):899-905.","DOI":"10.1016\/j.bbmt.2019.01.020"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0030","doi-asserted-by":"crossref","unstructured":"Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403-1410.","DOI":"10.1182\/blood-2014-10-604561"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0031","doi-asserted-by":"crossref","unstructured":"Montemurro M, Kiefer T, Sch\u00fcler F, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan\/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe H\u00e4mato-Onkologie OSHO-53 phase II study. Ann Oncol. 2007;18(4):665-671.","DOI":"10.1093\/annonc\/mdl458"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0032","doi-asserted-by":"crossref","unstructured":"Cote GM, Hochberg EP, Muzikansky A, et al. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012;18(1):76-83.","DOI":"10.1016\/j.bbmt.2011.07.006"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0033","doi-asserted-by":"crossref","unstructured":"Yoon DH, Lee DH, Choi DR, et al. Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. Bone Marrow Transplant. 2011;46(1):105-109.","DOI":"10.1038\/bmt.2010.71"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0034","unstructured":"Ahluwalia M, Baehring J, Brem H, et al. Continue NCCN guidelines panel disclosures NCCN guidelines version 2.2020 central nervous system cancers NCCN evidence blocks TM. Available at: www.nccn.org\/patients. Accessed May 25, 2020."},{"key":"10.1016\/j.bbmt.2020.08.012_bib0035","doi-asserted-by":"crossref","unstructured":"Elder J, Kim A, Cheerva A, Lucas K. Pharmacoeconomic impact of thiotepa-containing conditioning regimens in a pediatric hematopoetic stem cell transplant center. Biol Blood Marrow Transplant. 2015;21(2):S368-S369.","DOI":"10.1016\/j.bbmt.2014.11.593"},{"key":"10.1016\/j.bbmt.2020.08.012_bib0036","doi-asserted-by":"crossref","unstructured":"Kassam S, Chernucha E, O'Neill A, et al. High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom. Bone Marrow Transplant. 2017;52(9):1268-1272.","DOI":"10.1038\/bmt.2017.101"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120305048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120305048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:13:36Z","timestamp":1761059616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120305048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1083879120305048"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.08.012","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy","name":"copyright","label":"Copyright"}]}}